Five reasons to not prescribe opioids
Author: Lynn M Weekes
Published online: 7 September 2015
Around one in five Australians experience chronic pain. This is a complex condition to manage, with varied aetiology, pathology and presentation. Multimodal strategies are key, using a combination of different treatment modes to address the biological, social and psychological factors that contribute to the development of chronic pain.
Non-pharmacological strategies are an essential part of management. Medicines have a limited role in managing chronic pain, with guidelines recommending them only as an adjunct to non-pharmacological options. However, despite a lack of evidence to support long-term efficacy, the number of prescriptions for opioids continues to rise in Australia.
There are five key reasons not to prescribe opioids, and to consider deprescribing at every visit.
Adverse events
There is an increased risk of adverse events with extended opioid use: around 80% of people taking opioids long term will experience an adverse event. Most common are constipation, nausea and somnolence, but more serious adverse events can occur.
Limited evidence
Opioids have a limited role in chronic pain management because of a lack of evidence for their long-term benefit.
Central sensitisation
Central sensitisation and tolerance can occur within 4 weeks, limiting the viability of opioids as a clinical intervention.
Risk of abuse
There is a risk of abuse, misuse and addiction. People using opioids long term can develop an opioid-use disorder or exhibit drug-seeking behaviour.
Comorbidities
Co-existing conditions complicate management with opioids: major depression is the most common, and psychotropic medicines can interact with opioids to cause excessive sedation and respiratory depression.
The latest education program from NPS MedicineWise focuses on management of chronic non-cancer pain and is designed to help health professionals consolidate their knowledge on chronic pain management. The program is underpinned by evidence, current guidelines and best practice, and attracts continuing professional development points. To access the program, visit http://www.nps.org.au/chronic-pain.
Still Treating Yesterday's Risk? Reconsidering Antiviral Use for Mild-to-Moderate COVID-19 Cases in a Broadly Immune Population
Hadar Mudrik-Zohar, Tim Cutfield, Susan Morpeth, Thomas Hills, Eamon Duffy, Laura J. Edwards, Allen C. Cheng, Steven Y. C. Tong
Birth prevalence, clinical sequelae, and management of congenital cytomegalovirus infections in Australia, 1999–2023: a national prospective study
Ece Egilmezer, Suzy M Teutsch, Carlos Nunez, Stuart T Hamilton, Adam W Bartlett, Pamela Palasanthiran, Elizabeth J Elliott, William D Rawlinson
Medication delivery and dispensing interval preferences of people who use antihypertensive medications in Australia: a survey study
Carissa Bonner, Michael A Fajardo, Rachael M Keast, Emily Atkins, Niamh Chapman, Kristie R Weir, Anthony Rodgers, Aletta E Schutte
Concurrent use of hormonal long‐acting reversible contraception by women of reproductive age dispensed teratogenic medications, Australia, 2013–2021
Michelle KY Chen, Adrian Lim, Deshan F Sebaratnam
Concurrent use of hormonal long‐acting reversible contraception by women of reproductive age dispensed teratogenic medications, Australia, 2013–2021
Aaron E Boyce, Tony Caccetta, Jo‐Ann See, Rosemary L Nixon AM